Volume 4 (2016)

Review Articles

Feasibility and attractiveness of indication value-based pricing in key EU countries Mathias Flume, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, Nicolas Touchot

Original Research Articles

What makes a compliant Phase III and pre-launch patient advocacy strategy? Nick Hicks, Keith Allan, Christoph Thalheim, Paul Woods
The quality of life of Spanish patients with Huntington’s disease measured with H-QoL-I and EQ-5D Julie Dorey, Emilie Clay, Amine Khemiri, Anis Belhadj, Patricia Trigo Cubillo, Mondher Toumi
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials Eve Hanna, Cecile Rémuzat, Pascal Auquier, Mondher Toumi
Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles Edward Gibson, Najida Begum, Federico Martinón-Torres, Marco Aurélio Safadi, Alfred Sackeyfio, Judith Hackett, Sankarasubramanian Rajaram
Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole Craig Bennison, Stephanie Stephens, Benedicte Lescrauwaet, Ben van Hout, Timothy L. Jackson
Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations Katia Thokagevistk, Aurélie Millier, Leslie Lenert, Shamil Sadikhov, Santiago Moreno, Mondher Toumi
Advanced therapy medicinal products: current and future perspectives Eve Hanna, Cécile Rémuzat, Pascal Auquier, Mondher Toumi
The value of innovation under value-based pricing Santiago G, Moreno, Joshua A. Ray
Drug Pricing Reform in China: analysis of piloted approaches and potential impact of the reform Yixi Chen, Shanlian Hu, Peng Dong, Åsa Kornfeld, Patrycja Jaros, Jing Yan, Fangfang Ma, Mondher Toumi

Best Practice Papers

A training paradigm to enhance performance and safe use of an innovative neuroendovascular device Donald R. Ricci, Thomas R. Marotta, Howard A. Riina, Martina Wan, Joost De Vries

Position Papers

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement Michael Schlander, Silvio Garattini, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol Solà-Morales, Keith Tolley, Mondher Toumi